The role of the microenvironment in human immunodeficiency virus-associated classical Hodgkin lymphoma

Histopathology

Volumn 65, Issue 6, 2014, Pages 749-756

  Koulis, Athanasios ^a   Trivedi, Pritesh ^a   Ibrahim, Hazem ^a,c   Bower, Mark ^b   Naresh, Kikkeri N ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^c MANSOURA UNIVERSITY   (Egypt)

Author keywords

Classical Hodgkin lymphoma; Human immunodeficiency virus; Human immunodeficiency virus associated classical Hodgkin lymphoma; Immune system cells; Inflammation; Tumour microenvironment

Indexed keywords

CD123 ANTIGEN; CD20 ANTIGEN; CD3 ANTIGEN; CD30 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD57 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; GRANZYME B; TRANSCRIPTION FACTOR FOXP3; LEUKOCYTE ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ARTICLE; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARCINOGENESIS; CD4 CD8 RATIO; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CLASSICAL HODGKIN LYMPHOMA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HIV ASSOCIATED CLASSICAL HODGKIN LYMPHOMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; NODULAR SCLEROSIS HODGKIN LYMPHOMA; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; TISSUE MICROARRAY; TUMOR MICROENVIRONMENT; CD8+ T LYMPHOCYTE; COMPLICATION; HODGKIN DISEASE; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; VIROLOGY; YOUNG ADULT;

HUMAN IMMUNODEFICIENCY VIRUS;

ADOLESCENT; ADULT; ANTIGENS, CD; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; TISSUE ARRAY ANALYSIS; TUMOR MICROENVIRONMENT; YOUNG ADULT;

EID: 84919343380     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12458     Document Type: Article

References (23)

1. Bai M, Panoulas V, Papoudou-Bai A et al. B-cell differentiation immunophenotypes in classical Hodgkin lymphomas. Leuk. Lymphoma 2006; 47; 495-501.
2. Tzankov A, Bourgau C, Kaiser A et al. Rare expression of T-cell markers in classical Hodgkin's lymphoma. Mod. Pathol. 2005; 18; 1542-1549.
3. Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J. Clin. Oncol. 2011; 29; 1812-1826.
4. Swerdlow SH, Campo E, Harris NL et al. WHO classification of tumours of haematopoietic and lymphoid tissues, vol 2. 4th ed. Lyon: IARC publications, 2008.
5. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370; 59-67.
6. Shiels M, Pfeiffer R, Gail M et al. Cancer burden in the HIV-infected population in the United States. J. Natl Cancer Inst. 2011; 103; 753-762.
7. Bohlius J, Schmidlin K, Boué F et al. Collaboration of Observational HIV Epidemiological Research Europe. HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4+ T-cell lymphocytes. Blood 2011; 117; 6100-6108.
8. Powles T, Robinson D, Stebbing J et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J. Clin. Oncol. 2009; 27; 884-890.
9. Vaccher E, Spina M, Tirelli U. Clinical aspects and management of Hodgkin's disease and other tumours in HIV-infected individuals. Eur. J. Cancer 2001; 37; 1306-1315.
10. Herndier BG, Sanchez HC, Chang KL, Chen YY, Weiss LM. High prevalence of Epstein-Barr virus in the Reed-Sternberg cells of HIV-associated Hodgkin's disease. Am. J. Pathol. 1993; 142; 1073-1079.
11. Montoto S, Shaw K, Okosun J et al. HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. J. Clin. Oncol. 2012; 30; 4111-4116.
12. Khan G. Epstein-Barr virus, cytokines, and inflammation: a cocktail for the pathogenesis of Hodgkin's lymphoma? Exp. Hematol. 2006; 34; 399-406.
13. Carbone A, Gloghini A, Larocca L et al. Human immunodeficiency virus-associated Hodgkin's disease derives from post-germinal center B cells. Blood 1999; 93; 2319-2326.
14. Lim A, Tan D, Price P et al. Proportions of circulating T cells with a regulatory cell phenotype increase with HIV-associated immune activation and remain high on antiretroviral therapy. AIDS 2007; 21; 1525-1534.
15. Nigam P, Velu V, Kannanganat S et al. Expansion of FOXP3+ CD8 T cells with suppressive potential in colorectal mucosa following a pathogenic simian immunodeficiency virus infection correlates with diminished antiviral T cell response and viral control. J. Immunol. 2010; 184; 1690-1701.
16. Kiyasu J, Aoki R, Tanaka PY et al. FOXP3(+) regulatory and TIA-1(+) cytotoxic T lymphocytes in HIV-associated Hodgkin lymphoma. Pathol. Int. 2012; 62; 77-83.
17. Bosch Príncep R, Lejeune M, SalvadóUsach MT, JaénMartínez J, Pons FL, Alvaro Naranjo T. Decreased number of granzyme B+ activated CD8+ cytotoxic T lymphocytes in the inflammatory background of HIV-associated Hodgkin's lymphoma. Ann. Hematol. 2005; 84; 661-666.
18. Brunetta E, Hudspeth KL, Mavilio D. Pathologic natural killer cell subset redistribution in HIV-1 infection: new insights in pathophysiology and clinical outcomes. J. Leukoc. Biol. 2010; 88; 1119-1130.
19. Fogli M, Mavilio D, Brunetta E et al. Lysis of endogenously infected CD4+ T cell blasts by rIL-2 activated autologous natural killer cells from HIV-infected viremic individuals. PLoS Pathog. 2008; 4; e1000101.
20. Mavilio D, Lombardo G, Benjamin J et al. Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc. Natl Acad. Sci. USA 2005; 102; 2886-2891.
21. Parato KG, Kumar A, Badley AD et al. Normalization of natural killer cell function and phenotype with effective anti-HIV therapy and the role of IL-10. AIDS 2002; 16; 1251-1256.
22. Palmer BE, Blyveis N, Fontenot AP, Wilson CC. Functional and phenotypic characterization of CD57+CD4+ T cells and their association with HIV-1-induced T cell dysfunction. J. Immunol. 2005; 175; 8415-8423.
23. Chehimi J, Campbell DE, Azzoni L et al. Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals. J. Immunol. 2002; 168; 4796-4801.